
Expanded Approval, New Dosage Form for Olaparib in Recurrent Ovarian Cancer
A new oral dosage form of olaparib (Lynparza) has been approved as maintenance treatment in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
A new oral dosage form of olaparib (Lynparza), a PARP inhibitor, has been approved as maintenance treatment in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The tablet form has also been approved for women with advanced ovarian cancer who carry defects in the BRCA gene and who have received at least 3 lines of therapy, similar to olaparib capsules, which received
“Today’s approvals validate more than 10 years of dedicated research behind LYNPARZA, the world’s first PARP inhibitor, which now provides oncologists with the greater flexibility for use in terms of treatment settings. It builds on our recently-announced collaboration with Merck, which aims to further increase the number of treatment options available to patients,”
The FDA reviewed results from the phase 3
SOLO-2 met its primary endpoint of investigator-assessed PFS, with olaparib improving the median PFS (19.1 months) by over a year compared with the placebo (5.5 months) (hazard ratio [HR], 0.30; 95% CI, 0.22—0.41; P <.0001). PFS as measured by Blinded Independent Central Review evaluation demonstrated a median PFS of 30.2 months vs 5.5 months for placebo, representing an improvement of 24.7 months (HR, 0.25; 95% CI, 0.18—0.35; P <.0001).
The FDA also reviewed results from
More than 20% of patients experienced anemia, nausea, fatigue (including asthenia), vomiting, nasopharyngitis, diarrhea, arthralgia/myalgia, dysgeusia, headache, dyspepsia, decreased appetite, constipation, or stomatitis. Common pathologic abnormalities included decrease in hemoglobin, increase in mean corpuscular volume, decrease in lymphocytes, decrease in leukocytes, decrease in absolute neutrophil count, increase in serum creatinine, and decrease in platelets.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.